| ROCKET PHARMACEUTICALS |
| USA |
| Gesundheit |
| US77313F1066 / A2JA9Q |
| 9IP1 (Frankfurt) / RCKT (NASDAQ) |
| FRA:9IP1, ETR:9IP1, 9IP1:GR, NASDAQ:RCKT |
| - |
| https://www.rocketpharma... |
|
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with an emphasis on inherited cardiovascular disorders, hematology, and immunology. The company’s programs are built aro..
>Volltext.. |
| 242.45 Mio. EUR |
| 14.32 Mio. EUR |
| - |
| -164.23 Mio. EUR |
| -15.55 Mio. EUR |
| -0.15 EUR |
| 22.36 Mio. EUR |
| 202.39 Mio. EUR |
| -153.5 Mio. EUR |
| 9.06 |
| - |
| 93.08% |
| - |
| - |
| - |
| ROCKET PHARMACEUTICALS, ROCKET PHARMA, ROCKET PHARMACEUTICAL |
| 13.11.26 |
|